Search Results - "MEERBEECK, Jan P. Van"

Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis by HOLLEVOET, Kevin, REITSMA, Johannes B, SCHNEIDER, Joachim, MULEY, Thomas, DI SERIO, Francesca, BAAS, Paul, TOMASETTI, Marco, RAI, Alex J, MEERBEECK, Jan P. Van, CREANEY, Jenette, GRIGORIU, Bogdan D, ROBINSON, Bruce W, SCHERPEREEL, Arnaud, CRISTAUDO, Alfonso, PASS, Harvey I, NACKAERTS, Kristiaan, RODRIGUEZ PORTAL, José A

“…Mesothelin is currently considered the best available serum biomarker of malignant pleural mesothelioma. To examine the diagnostic accuracy and use of serum…”
Get full text

Exhaled breath to screen for malignant pleural mesothelioma: a validation study by Lamote, Kevin, Vynck, Matthijs, Thas, Olivier, Van Cleemput, Joris, Nackaerts, Kristiaan, van Meerbeeck, Jan P

“…Malignant pleural mesothelioma (MPM) is predominantly caused by asbestos exposure and has a poor prognosis. Breath contains volatile organic compounds (VOCs)…”
Get full text

Volatile organic compounds in human matrices as lung cancer biomarkers: a systematic review by Janssens, Eline, van Meerbeeck, Jan P, Lamote, Kevin

“…•Volatile organic compounds are promising biomarkers for lung cancer diagnosis.•Different human matrices can be explored as sources of volatile…”
Get full text

Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression by Marcq, Elly, Audenaerde, Jonas Rm Van, Waele, Jorrit De, Jacobs, Julie, Loenhout, Jinthe Van, Cavents, Glenn, Pauwels, Patrick, Meerbeeck, Jan P van, Smits, Evelien Lj

“…In light of the promising results of immune checkpoint blockade (ICPB) in malignant pleural mesothelioma (MPM), we investigated the effect of different…”
Get full text

Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials by Zikos, Efstathios, MS, Ghislain, Irina, MS, Coens, Corneel, MS, Ediebah, Divine E, MS, Sloan, Elizabeth, MS, Quinten, Chantal, MS, Koller, Michael, Prof, van Meerbeeck, Jan P, Prof, Flechtner, Hans-Henning, Prof, Stupp, Roger, Prof, Pallis, Athanasios, PhD, Czimbalmos, Agnes, MD, Sprangers, Mirjam A G, Prof, Bottomley, Andrew, PhD

“…Summary Small-cell lung cancer represents about 15% of all lung cancers; increasingly, randomised controlled trials of this disease measure the health-related…”
Get full text

Small-cell lung cancer by van Meerbeeck, Jan P, Prof, Fennell, Dean A, FRCP, De Ruysscher, Dirk KM, Prof

“…Summary The incidence and mortality of small-cell lung cancer worldwide make this disease a notable health-care issue. Diagnosis relies on histology, with the…”
Get full text

ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma by Scherpereel, Arnaud, Opitz, Isabelle, Berghmans, Thierry, Psallidas, Ioannis, Glatzer, Markus, Rigau, David, Astoul, Philippe, Bölükbas, Servet, Boyd, Jeanette, Coolen, Johan, De Bondt, Charlotte, De Ruysscher, Dirk, Durieux, Valerie, Faivre-Finn, Corinne, Fennell, Dean, Galateau-Salle, Francoise, Greillier, Laurent, Hoda, Mir Ali, Klepetko, Walter, Lacourt, Aude, McElnay, Phil, Maskell, Nick A, Mutti, Luciano, Pairon, Jean-Claude, Van Schil, Paul, van Meerbeeck, Jan P, Waller, David, Weder, Walter, Cardillo, Giuseppe, Putora, Paul Martin

“…The European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society…”
Get full text

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial by Faivre-Finn, Corinne, Prof, Snee, Michael, DM, Ashcroft, Linda, MSc, Appel, Wiebke, MD, Barlesi, Fabrice, Prof, Bhatnagar, Adityanarayan, MD, Bezjak, Andrea, MD, Cardenal, Felipe, PhD, Fournel, Pierre, Prof, Harden, Susan, DM [Oxon], Le Pechoux, Cecile, MD, McMenemin, Rhona, MSc, Mohammed, Nazia, FRCR, O'Brien, Mary, MD, Pantarotto, Jason, MD, Surmont, Veerle, Prof, Van Meerbeeck, Jan P, Prof, Woll, Penella J, Prof, Lorigan, Paul, Prof, Blackhall, Fiona, Prof

“…Summary Background Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose…”
Get full text

Lung cancer screening in Europe: where are we in 2021? by van Meerbeeck, Jan P., Franck, Caro

“…This manuscript reviews the recent evidence obtained in lung cancer screening with low dose spiral CT-scan (LDSCT) and focuses on the issues associated with…”
Get full text

The Effect of Clinical Covariates on the Diagnostic and Prognostic Value of Soluble Mesothelin and Megakaryocyte Potentiating Factor by Hollevoet, Kevin, PhD, Nackaerts, Kristiaan, MD, PhD, Thas, Olivier, PhD, Thimpont, Joël, MD, Germonpré, Paul, MD, PhD, De Vuyst, Paul, MD, PhD, Bosquée, Lionel, MD, Legrand, Catherine, PhD, Kellen, Eliane, MD, PhD, Kishi, Yoshiro, PhD, Delanghe, Joris R., MD, PhD, van Meerbeeck, Jan P., MD, PhD

“…Background Soluble mesothelin (SM) and megakaryocyte potentiating factor (MPF) are serum biomarkers of mesothelioma. This study examined the effect of clinical…”
Get full text

Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis by Schillebeeckx, Eline, van Meerbeeck, Jan P., Lamote, Kevin

“…Malignant pleural mesothelioma (MPM) is characterised by late-stage diagnosis and poor prognosis. Currently, no screening tool is advocated and diagnosis is…”
Get full text

ESR/ERS statement paper on lung cancer screening by Kauczor, Hans-Ulrich, Baird, Anne-Marie, Blum, Torsten Gerriet, Bonomo, Lorenzo, Bostantzoglou, Clementine, Burghuber, Otto, Čepická, Blanka, Comanescu, Alina, Couraud, Sébastien, Devaraj, Anand, Jespersen, Vagn, Morozov, Sergey, Agmon, Inbar Nardi, Peled, Nir, Powell, Pippa, Prosch, Helmut, Ravara, Sofia, Rawlinson, Janette, Revel, Marie-Pierre, Silva, Mario, Snoeckx, Annemiek, van Ginneken, Bram, van Meerbeeck, Jan P., Vardavas, Constantine, von Stackelberg, Oyunbileg, Gaga, Mina

“…In Europe, lung cancer ranks third among the most common cancers, remaining the biggest killer. Since the publication of the first European Society of…”
Get full text

Recent developments in the treatment of small cell lung cancer by Hiddinga, Birgitta I., Raskin, Jo, Janssens, Annelies, Pauwels, Patrick, Van Meerbeeck, Jan P.

“…Small cell lung cancer (SCLC) comprises about 15% of all lung cancers. It is an aggressive disease, with early metastasis and a poor prognosis. Until recently,…”
Get full text

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC by Manegold, Christian, Dingemans, Anne-Marie C, Gray, Jhanelle E, Nakagawa, Kazuhiko, Nicolson, Marianne, Peters, Solange, Reck, Martin, Wu, Yi-Long, Brustugun, Odd Terje, Crinò, Lucio, Felip, Enriqueta, Fennell, Dean, Garrido, Pilar, Huber, Rudolf M, Marabelle, Aurélien, Moniuszko, Marcin, Mornex, Françoise, Novello, Silvia, Papotti, Mauro, Pérol, Maurice, Smit, Egbert F, Syrigos, Kostas, van Meerbeeck, Jan P, van Zandwijk, Nico, Yang, James Chih-Hsin, Zhou, Caicun, Vokes, Everett

“…Over the past few years, there have been considerable advances in the treatments available to patients with metastatic or locally advanced NSCLC, particularly…”
Get more information

Initial analysis of the international association for the study of lung cancer mesothelioma database by Rusch, Valerie W, Giroux, Dorothy, Kennedy, Catherine, Ruffini, Enrico, Cangir, Ayten K, Rice, David, Pass, Harvey, Asamura, Hisao, Waller, David, Edwards, John, Weder, Walter, Hoffmann, Hans, van Meerbeeck, Jan P

“…The current staging system for malignant pleural mesothelioma (MPM) is controversial. To plan revisions of this system, the International Association for the…”
Get more information

The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing by Hylebos, Marieke, Van Camp, Guy, van Meerbeeck, Jan P, Op de Beeck, Ken

“…Malignant pleural mesothelioma (MPM) is a rare yet aggressive tumor that is causally associated with-mostly professional-asbestos exposure. Given the long…”
Get more information

Evaluation of the solitary pulmonary nodule: size matters, but do not ignore the power of morphology by Snoeckx, Annemie, Reyntiens, Pieter, Desbuquoit, Damien, Spinhoven, Maarten J., Van Schil, Paul E., van Meerbeeck, Jan P., Parizel, Paul M.

“…Subsequent to the widespread use of multidetector computed tomography and growing interest in lung cancer screening, small pulmonary nodules are more…”
Get full text

Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot? by Lagniau, Sabrina, Lamote, Kevin, van Meerbeeck, Jan P, Vermaelen, Karim Y

“…Early diagnosis of malignant pleural mesothelioma (MPM) is a challenge for clinicians. The disease is usually detected in an advanced stage which precludes…”
Get full text

Targeting immune checkpoints: New opportunity for mesothelioma treatment? by Marcq, Elly, Pauwels, Patrick, van Meerbeeck, Jan P, Smits, Evelien L.J

“…Highlights • Working mechanism and expression pattern of immune checkpoints. • Clinical data of immune checkpoint blocking antibodies are very promising. •…”
Get full text

Use of the lung cancer–specific Quality of Life Questionnaire EORTC QLQ‐LC13 in clinical trials: A systematic review of the literature 20 years after its development by Koller, Michael, Warncke, Sophie, Hjermstad, Marianne J., Arraras, Juan, Pompili, Cecilia, Harle, Amelie, Johnson, Colin D., Chie, Wei‐Chu, Schulz, Christian, Zeman, Florian, van Meerbeeck, Jan P., Kuliś, Dagmara, Bottomley, Andrew

“…The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire‐Lung Cancer 13 (QLQ‐LC13) covers 13 typical symptoms of…”
Get full text